Capricor Therapeutics Inc. reported cash, cash equivalents and marketable securities of approximately $98.6 million as of September 30, 2025, down from $151.5 million at December 31, 2024. Revenues for the third quarter of 2025 were $0, compared to $2.3 million in the same period of 2024. For the first nine months of 2025, revenues were $0, compared to $11.1 million for the first nine months of 2024. Total operating expenses for the third quarter of 2025 were $26.3 million, up from $15.3 million in the third quarter of 2024. Operating expenses for the first nine months of 2025 were $79.0 million, compared to $46.0 million in the same period of 2024. During the period, Capricor advanced its HOPE-3 Phase 3 trial of Deramiocel for the treatment of Duchenne muscular dystrophy, with topline results expected in the fourth quarter of 2025 and commercial launch preparations underway for a potential 2026 market introduction. The company also continued its NIAID-sponsored Phase 1 trial of the StealthX exosome-based vaccine, with initial data expected in the first quarter of 2026.